Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
attenuated reassortant lymphocytic choriomeningitis virus
- Development stage
- Preclinical
- Lead developer
- HOOKIPA Pharma
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intraperitoneal, Intravenous, Intracranial (in Animal Models)
01
Overview
An **attenuated reassortant lymphocytic choriomeningitis virus** is an engineered, live, replication-competent or -deficient viral vector derived from LCMV exhibiting reduced virulence due to genetic modifications such as segment reassortment or codon deoptimization. These modifications result in reduction of viral protein expression or altered segment structure, substantially lowering pathogenicity but preserving immunogenicity. Such viruses have been developed as vaccine candidates, able to confer protective immunity against wild-type LCMV challenge in animal models, and engage robust cellular and antibody responses. Genome rearrangement (e.g. swapping genes or recoding nucleoprotein using rare codons) is used to achieve attenuation. Preclinical and early-phase clinical work demonstrates efficacy and safety for infectious disease prevention and immunotherapy platforms[1][5][7].
- Other names
- live-attenuated LCMVartLCMVrecombinant LCMVrLCMV/TransSrLCMV/NP~CD1~rLCMV/NP~CD2~
02
Targets
α-DG (Alpha-dystroglycan)
Beyond the preview
Go deeper on attenuated reassortant lymphocytic choriomeningitis virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on attenuated reassortant lymphocytic choriomeningitis virus.